Quyen Ngo-Metzger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Quyen Ngo-Metzger has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Aiyu Chen
Kaiser Permanente Southern California, Pasadena, CA
1 shared publication - Alex H. Krist
Virginia Commonwealth University
1 shared publication Alex R. Kemper
Nationwide Children's Hospital, Columbus, Ohio (A.R.K.)
1 shared publicationAmanda Borsky
Agency for Healthcare Research and Quality, Rockville, Maryland (J.M., A.B.)
1 shared publicationAmanda E. Borsky
From the Agency for Healthcare Research and Quality, Rockville, MD (SZ, PS, HT, AB, ASB); Department of Health Law, Policy, and Management, School of Public Health, Boston University, Boston, MA (PS); Kaiser Permanente School of Medicine (QN-M)
1 shared publication- Angela Fagerlin
Department of Population Health Sciences, Spencer Fox Eccles School of Medicine at University of Utah , Salt Lake City, Utah
1 shared publication
Latest Publications
- Open Access
The MyLungHealth study protocol: a pragmatic patient-randomised controlled trial to evaluate a patient-centred, electronic health record-integrated intervention to enhance lung cancer screening in primary care
Introduction Early lung cancer screening (LCS) through low-dose CT (LDCT) is crucial but underused due to various barriers, including incomplete or inaccurate patient smoking data in the electronic health record and limited time for shared decision-making. The objective of this trial is to investigate a patient-centred intervention, MyLungHealth, delivered through the patient portal. The intervention is designed to improve LCS rates through increased identification of eligible patients and informed decision-making. Methods and analysis MyLungHealth is a multisite pragmatic trial, involving University of Utah Health and New York University Langone Health primary care clinics. The MyLungHealth intervention was developed using a user-centred design process, informed by patient and provider focus groups and interviews. The intervention’s effectiveness will be evaluated through a patient-randomised trial, comparing the combined use of MyLungHealth and DecisionPrecision+ (a provider-focused shared decision-making intervention) against DecisionPrecision+ alone. The first study hypothesis is that among patients aged 50–79 with uncertain LCS eligibility (eg, 10–19 pack-years or unknown pack-years or unknown quit date for individuals who used to smoke), MyLungHealth eligibility questionnaires will result in increased identification of LCS-eligible patients (n~26 729 patients). The second study hypothesis is that among patients aged 50–79 with documented LCS eligibility (20+ pack-years, quit within the last 15 years if individuals who used to smoke, and no recent screening or screening discussion), MyLungHealth education will result in increased LDCT ordering (n~4574 patients). Primary outcomes will be identification of LCS-eligible patients among individuals with uncertain LCS eligibility and LDCT ordering rates among individuals with documented LCS eligibility. Ethics and dissemination The protocol was approved by the University of Utah Institutional Review Board (# 00153806). The patient data collected for this study will not be shared publicly due to the sensitive nature of the patient health information and the fact that we will not be obtaining written informed consent to allow public sharing of their data. Results will be disseminated through peer-reviewed publications. Trial registration number Clinicaltrials.gov, NCT06338592.
Open AccessThe MyLungHealth study protocol: a pragmatic patient-randomised controlled trial to evaluate a patient-centred, electronic health record-integrated intervention to enhance lung cancer screening in primary care
Introduction Early lung cancer screening (LCS) through low-dose CT (LDCT) is crucial but underused due to various barriers, including incomplete or inaccurate patient smoking data in the electronic health record and limited time for shared decision-making. The objective of this trial is to investigate a patient-centred intervention, MyLungHealth, delivered through the patient portal. The intervention is designed to improve LCS rates through increased identification of eligible patients and informed decision-making. Methods and analysis MyLungHealth is a multisite pragmatic trial, involving University of Utah Health and New York University Langone Health primary care clinics. The MyLungHealth intervention was developed using a user-centred design process, informed by patient and provider focus groups and interviews. The intervention’s effectiveness will be evaluated through a patient-randomised trial, comparing the combined use of MyLungHealth and DecisionPrecision+ (a provider-focused shared decision-making intervention) against DecisionPrecision+ alone. The first study hypothesis is that among patients aged 50–79 with uncertain LCS eligibility (eg, 10–19 pack-years or unknown pack-years or unknown quit date for individuals who used to smoke), MyLungHealth eligibility questionnaires will result in increased identification of LCS-eligible patients (n~26 729 patients). The second study hypothesis is that among patients aged 50–79 with documented LCS eligibility (20+ pack-years, quit within the last 15 years if individuals who used to smoke, and no recent screening or screening discussion), MyLungHealth education will result in increased LDCT ordering (n~4574 patients). Primary outcomes will be identification of LCS-eligible patients among individuals with uncertain LCS eligibility and LDCT ordering rates among individuals with documented LCS eligibility. Ethics and dissemination The protocol was approved by the University of Utah Institutional Review Board (# 00153806). The patient data collected for this study will not be shared publicly due to the sensitive nature of the patient health information and the fact that we will not be obtaining written informed consent to allow public sharing of their data. Results will be disseminated through peer-reviewed publications. Trial registration number Clinicaltrials.gov, NCT06338592.
- 1 June 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (6) , 895-896
Diabetes Screening: Different Thresholds for Different Racial/Ethnic Groups
In their article, Aggarwal and colleagues report a study that found that persons in underrepresented racial/ethnic groups have higher prevalence rates of diabetes at a lower body mass index and you...
- 1 June 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (6) , 895-896
Diabetes Screening: Different Thresholds for Different Racial/Ethnic Groups
In their article, Aggarwal and colleagues report a study that found that persons in underrepresented racial/ethnic groups have higher prevalence rates of diabetes at a lower body mass index and you...
- 1 February 2022
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 62 (2) , e77-e86
Characteristics of Scientific Evidence Informing Changed U.S. Preventive Services Task Force Insufficient Evidence Statements
- 1 February 2022
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 62 (2) , e77-e86
Characteristics of Scientific Evidence Informing Changed U.S. Preventive Services Task Force Insufficient Evidence Statements
- Open Access
- 1 August 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (8) , 1183-1186
COVID-19 Inequities Across Multiple Racial and Ethnic Groups: Results From an Integrated Health Care Organization
- 1 August 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (8) , 1183-1186
Open AccessCOVID-19 Inequities Across Multiple Racial and Ethnic Groups: Results From an Integrated Health Care Organization
- Open Access
- 15 September 2020
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 173 (6) , 461-467
Developing Primary Care–Based Recommendations for Social Determinants of Health: Methods of the U.S. Preventive Services Task Force
This position paper from the U.S. Preventive Services Task Force (USPSTF) highlights social determinants already included in USPSTF recommendations and proposes a process by which other social dete... The purpose of the U.S. Preventive Services Task Force (USPSTF) is to provide evidence-based recommendations on primary care screening, behavioral counseling, and preventive medications. A person's...
- 15 September 2020
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 173 (6) , 461-467
Open AccessDeveloping Primary Care–Based Recommendations for Social Determinants of Health: Methods of the U.S. Preventive Services Task Force
This position paper from the U.S. Preventive Services Task Force (USPSTF) highlights social determinants already included in USPSTF recommendations and proposes a process by which other social dete... The purpose of the U.S. Preventive Services Task Force (USPSTF) is to provide evidence-based recommendations on primary care screening, behavioral counseling, and preventive medications. A person's...
- Open Access
- 8 November 2019
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 32 (6) , 807-817
Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal
Background: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality in the United States. The purpose of this study is to examine the rates of statin use for secondary prevention of ASCVD events in the United States over the last decade and determine whether disparities in the treatment of ASCVD still persist among women and racial/ethnic minorities. Methods: We conducted a trend analysis using data from 2008 through 2016 to describe age-adjusted trends in the use of statins for secondary prevention using the Medical Expenditure Panel Survey. We also conducted a multivariable logistic regression analysis to determine whether sociodemographic characteristics are associated with statin use during the 3 years that followed the publication of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline (2014 through 2016). Results: The prevalence of statin use among those with a history of ASCVD remained unchanged from 2008 through 2016. In 2014 to 2016, more than 40% of those aged 40 years and older with a history of ASCVD did not use statins, corresponding to approximately 9.5 million Americans. Increasing age and having been diagnosed with high cholesterol (odds ratio [OR], 6.22; P < .001) were associated with higher odds of statin use while being female (OR, 0.65; P < .001) or Hispanic (OR, 0.69; P = .011) were associated with lower odds of statin use. Conclusions: Our study found there was no increase in the national rates of statin use following the ACC/AHA 2013 secondary prevention guideline and the availability of generic statins. Significant gender and ethnic disparities in ASCVD treatment remained in the United States.
- 8 November 2019
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 32 (6) , 807-817
Open AccessStatin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal
Background: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality in the United States. The purpose of this study is to examine the rates of statin use for secondary prevention of ASCVD events in the United States over the last decade and determine whether disparities in the treatment of ASCVD still persist among women and racial/ethnic minorities. Methods: We conducted a trend analysis using data from 2008 through 2016 to describe age-adjusted trends in the use of statins for secondary prevention using the Medical Expenditure Panel Survey. We also conducted a multivariable logistic regression analysis to determine whether sociodemographic characteristics are associated with statin use during the 3 years that followed the publication of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline (2014 through 2016). Results: The prevalence of statin use among those with a history of ASCVD remained unchanged from 2008 through 2016. In 2014 to 2016, more than 40% of those aged 40 years and older with a history of ASCVD did not use statins, corresponding to approximately 9.5 million Americans. Increasing age and having been diagnosed with high cholesterol (odds ratio [OR], 6.22; P < .001) were associated with higher odds of statin use while being female (OR, 0.65; P < .001) or Hispanic (OR, 0.69; P = .011) were associated with lower odds of statin use. Conclusions: Our study found there was no increase in the national rates of statin use following the ACC/AHA 2013 secondary prevention guideline and the availability of generic statins. Significant gender and ethnic disparities in ASCVD treatment remained in the United States.